title: Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma.
abstract: Plasmablastic lymphoma (PBL) is an aggressive lymphoma classified by the World Health Organization as a subtype of diffuse large B-cell lymphoma that shares many morphologic and immunophenotypic features with multiple myeloma. It is extremely rare in immunocompetent patients. Because of the small number of patients reported, this rare lymphoma remains a poorly characterized and understood entity with presently no standard recommendations regarding the optimal treatment. Herein, we report a dramatic clinical response coupled with tumor lysis syndrome to a bortezomib-based treatment in an HIV-negative patient with refractory plasmablastic lymphoma.
authors.affiliation: University of Rochester, New York, NY, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Lipstein
authors.forename: Owen
authors.initials: O
authors.lastname: O'Connor
authors.forename: Francesca
authors.initials: F
authors.lastname: Montanari
authors.forename: Luca
authors.initials: L
authors.lastname: Paoluzzi
authors.forename: Danielle
authors.initials: D
authors.lastname: Bongero
authors.forename: Govind
authors.initials: G
authors.lastname: Bhagat
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D015658:HIV Infections / Q000473:pathology; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D008297:Male; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D015275:Tumor Lysis Syndrome / Q000209:etiology* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib